Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Non Operating Income: 2020-2024

Historic Other Non Operating Income for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $416,000.

  • Monte Rosa Therapeutics' Other Non Operating Income rose 81.05% to -$29,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 520.82%. This contributed to the annual value of $416,000 for FY2024, which is 144.73% up from last year.
  • As of FY2024, Monte Rosa Therapeutics' Other Non Operating Income stood at $416,000, which was up 144.73% from -$930,000 recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Other Non Operating Income ranged from a high of $416,000 in FY2024 and a low of -$930,000 during FY2023.
  • Moreover, its 3-year median value for Other Non Operating Income was $10,000 (2022), whereas its average is -$168,000.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first tumbled by 9,400.00% in 2023, then spiked by 144.73% in 2024.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' Other Non Operating Income stood at -$198,000 in 2020, then climbed by 18.18% to -$162,000 in 2021, then spiked by 106.17% to $10,000 in 2022, then plummeted by 9,400.00% to -$930,000 in 2023, then skyrocketed by 144.73% to $416,000 in 2024.